Outlook Therapeutics Announces Resubmission of Biologics License Application to U.S. FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg)
Go back to Outlook Therapeutics Announces Resubmission of Biologics License Application to U.S. FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg)| Otter Lake Resources, Inc. New (NASDAQ: OTLK) | Delayed: 1.73 -0.1 (5.46%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.83 | 52 Week High | $0.03 | |||
| Open | $1.74 | 52 Week Low | $0.01 | |||
| Day High | $1.87 | P/E | N/A | |||
| Day Low | $1.70 | EPS | $0.00 | |||
| Volume | 6,605,339 | |||||
